论文部分内容阅读
目的研究替比夫定治疗HBeAg阳性慢性乙型肝炎的近期疗效。方法 78例HBeAg阳性慢性乙型肝炎患者随机分为两组,治疗组45例采用替比夫定治疗,对照组33例采用拉米夫定治疗,疗程48周,定期观察两组疗效。结果治疗48周后,两组患者在ALT复常率和HBeAg转换率比较,无统计学差异(P>0.05)。治疗过程中定期比较两组患者HBVDNA阴转率和HBeAg阴转率,差异均有统计学意义(P<0.05)。治疗48周时替比夫定组血清HBVDNA自基线下降值为6.07log10,与对照组相比有统计学差异(P<0.01)。结论替比夫定治疗可以快速、有效降低HBVDNA,促进HBeAg阴转,其安全性和耐受性良好。
Objective To study the short-term effect of telbivudine in the treatment of HBeAg-positive chronic hepatitis B patients. Methods Seventy-eight patients with HBeAg-positive chronic hepatitis B were randomly divided into two groups. The treatment group was treated with telbivudine and the control group was treated with lamivudine for 48 weeks. The curative effect was observed regularly. Results After treatment for 48 weeks, there was no significant difference between the two groups in ALT normalization rate and HBeAg conversion rate (P> 0.05). During the course of treatment, HBVDNA negative rate and HBeAg negative rate were compared between two groups on a regular basis, the differences were statistically significant (P <0.05). Serum HBVDNA level was 6.07log10 in telbivudine group after 48 weeks treatment, which was significantly lower than that in control group (P <0.01). Conclusion The telbivudine treatment can rapidly and effectively reduce HBVDNA and promote HBeAg negative conversion with good safety and tolerability.